More GBL Marketers Sent Warning Letters By FDA
This article was originally published in The Tan Sheet
Three companies that refuse to voluntarily products containing gamma-butyrolactone (GBL) received March 8 warning letters from FDA. The letters went to Invigorate International, Cabot Industries and Nutritional Concepts.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC